# A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

> **NCT03050398** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** letrozole

## Key facts

- **NCT ID:** NCT03050398
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-07
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-03-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** GCP issues.
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050398, "A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03050398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*